Table 3.
| Day 3 | Day 7 | |||||||
|---|---|---|---|---|---|---|---|---|
| Measure subscale | PLA-Low | PLA-Higher | FG-Low | FG-Higher | PLA-Low | PLA-Higher | FG-Low | FG-Higher |
| Trail Making Test | ||||||||
| Part A# | 49.0 (1.8) | 48.8 (2.6) | 52.0 (1.5) | 49.5 (2.9) | 51.1 (1.8) | 54.7 (2.7) | 53.7 (1.5) | 57.7 (2.9) |
| Part B | 53.5 (2.1) | 51.5 (2.9) | 54.7 (1.7) | 48.8 (3.3) | 58.6 (2.1) | 55.6 (3.1) | 57.4 (1.7) | 57.3 (3.3) |
| Stroop Color-Naming Test | ||||||||
| Word-reading | 48.1 (1.5) | 49.5 (2.0) | 50.3 (1.2) | 48.5 (2.3) | 52.0 (1.5) | 53.4 (2.1) | 53.5 (1.2) | 52.7 (2.3) |
| Color-naming | 49.2 (1.4) | 50.9 (2.0) | 48.7 (1.2) | 47.5 (2.3) | 53.0 (1.4) | 54.8 (2.1) | 51.5 (1.2) | 52.3 (2.3) |
| Interference* | 49.2 (1.3) | 53.3 (1.8) | 52.4 (1.0) | 50.6 (2.0) | 51.4 (1.3) | 55.8 (1.9) | 53.9 (1.0) | 58.6 (2.0) |
| Conners’ Continuous Performance Test-II | ||||||||
| Omissions | 45.5 (1.6) | 45.1 (2.2) | 45.2 (1.3) | 44.0 (2.7) | 43.2 (1.6) | 44.6 (2.3) | 44.8 (1.3) | 42.2 (2.7) |
| Commissions | 43.1 (1.5) | 43.7 (2.1) | 42.5 (1.2) | 42.5 (2.6) | 40.7 (1.5) | 41.7 (2.1) | 41.8 (1.2) | 38.9 (2.6) |
| Hit RT | 49.3 (2.0) | 48.2 (2.7) | 49.1 (1.6) | 50.0 (3.3) | 49.2 (2.0) | 44.6 (2.8) | 51.7 (1.6) | 51.1 (3.3) |
For each neurocognitive measure, Day 3 and 7 T-scores for the four groups: placebo/low AW (PLA-Low); placebo/higher AW (PLA-Higher); flumazenil/gabapentin/low AW (FG-Low); and flumazenil/gabapentin/higher AW (FG-Higher). Figures are least squares means (standard errors) from the linear mixed models.
#
p < .05 for interaction between AW group and time.
*
p < .05 for interaction between AW group, medication group, and time.